Evolving Role of Biomarkers in Prostate Cancer

The panel of experts in prostate cancer offers a comprehensive overview of prostate cancer diagnosis, emphasizing the role of prostate-specific antigen (PSA) testing in screening for the disease.

The key opinion leaders explore the challenges and limitations associated with using prostate-specific antigen (PSA) as a biomarker for prostate cancer detection and monitoring.

The panel emphasizes the crucial need for swift biomarker and genetic testing to facilitate timely and effective patient care in prostate cancer management.

Prostate cancer management experts share their clinical insights on selecting appropriate serum, urine, and/or tissue biomarkers, highlighting specific scenarios that warrant each type of test.

The key opinion leaders explore risk factors for prostate cancer, detailing both general risk groups and high-risk populations more susceptible to developing the disease.

Medical oncologists explore risk stratification strategies for newly diagnosed patients with prostate cancer, emphasizing the significant role of the Gleason score in diagnosis and prognosis.

The panelists examine the challenges and limitations they've faced when using the Gleason score for risk assessment in prostate cancer patients, while also highlighting how biomarker testing has informed and guided their treatment strategies.

The key opinion leaders explore various treatment approaches for prostate cancer, including surgery, radiation, and hormone therapy, explaining how biomarker results influence their treatment choices. They also detail the specific criteria they use to select between treatment options based on biomarker testing outcomes.

The panel examines the challenges associated with effectively interpreting and applying biomarker test results in prostate cancer management and treatment decision-making.

The panel explores the role of biomarkers in monitoring disease progression for prostate cancer patients on active surveillance, discussing how these tests aid in detecting changes that may warrant intervention.

The panel examines the significance of biomarkers in assessing therapy outcomes for prostate cancer patients, while also exploring the concept of absolute benefit in metastasis risk when adding androgen deprivation therapy (ADT) to radiation therapy for newly diagnosed cases.

The key opinion leaders explore strategies for integrating newly available diagnostic tests into the existing treatment paradigm and patient journey.

Prostate cancer specialists share their insights on anticipated future advancements that could significantly influence prostate cancer management strategies.

The panel explores promising biomarker research that has the potential to significantly impact patient care in prostate cancer.

The panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.

Tim A. Richardson, MD, outlines the 2 key scenarios for utilizing genetic testing in clinical practice.

APPs can help in introducing genetic testing and in the interpretation of results, according to Kara Cossis, PA-C, MPH.

“Before long, what we do, how we do it, and when we do it might solely be based off of those genetic testing results,” says Tim Richardson, MD.

Sieber shares his thoughts on the potential for universal genetic testing to become a standard of care practice for patients with prostate cancer.